Glutamine

MuscleTech® and Trust Group Reach Manufacturing and Marketing Agreement For The Brazilian Market

Retrieved on: 
Wednesday, April 3, 2024
Science, Glutamine, News, Elite, Athlete, Trust, Diet, Creatine, Dulce de leche

Trust Group has been a MuscleTech® distributor in Brazil since 2015 with the ability to market and sell MuscleTech® products, including access to its rights and trademarks, but those products were previously made and manufactured in North America.

Key Points: 
  • Trust Group has been a MuscleTech® distributor in Brazil since 2015 with the ability to market and sell MuscleTech® products, including access to its rights and trademarks, but those products were previously made and manufactured in North America.
  • “Since the inception of the MuscleTech® brand in 1995, the brand continues to fuel bodybuilders and other athletes with supplements backed by science.
  • By partnering with Trust Group, we are finally in a position to be able to make MuscleTech® products widely available and bring new sports nutrition innovations to our Brazilian fans,” said Scott Welch, Associate Director, MuscleTech®, on the agreement.
  • “Because of the unique challenges presented by Brazil as a market, the MuscleTech® portfolio had previously been fairly limited,” said Juliano Victorino, CEO of the Trust Group.

Revolutionizing Wellness: Consumer Automotive Finance, Inc. Unveils Groundbreaking Mushroom Immune Booster and More in Exciting Supplement Expansion

Retrieved on: 
Tuesday, November 14, 2023
Creatine, CAFI, Medicine, BCCA, Collagen, Health, Glutamine

Melbourne, Fla, Nov. 14, 2023 /PRNewswire/ -- Breaking New Ground in Health and Wellness: Consumer Automotive Finance, Inc. (OTCPK: CAFI) proudly steps into the future of fitness and health with its latest innovative launches. We're thrilled to introduce an exhilarating range of new products under our esteemed 51 supplement and nutrition brand, setting a new benchmark in the dynamic health and wellness industry.

Key Points: 
  • We're thrilled to introduce an exhilarating range of new products under our esteemed 51 supplement and nutrition brand, setting a new benchmark in the dynamic health and wellness industry.
  • Leading the Charge with 51's Mushroom Immune Booster: Dive into the thriving mushroom supplement market with our trailblazing Mushroom Immune Booster.
  • 51 has meticulously crafted this top-tier product, responding swiftly to market demands and delivering unparalleled quality.
  • Joining our Mushroom Immune Booster are our meticulously formulated Creatine and Glutamine supplements, alongside our delightfully tasty Probiotic and Collagen gummies.

Emmaus Life Sciences Reports Q3 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
OTCQX, Expense, Sickle cell disease, Cryptocurrency, Reinsurance, Glutamine, MENA

TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

Key Points: 
  • TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
  • Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.
  • Total operating expenses for the nine months ended September 30, 2023 were $19.2 million, compared with $15.7 million for the same period in 2022.
  • At September 30, 2023, the company had cash and cash equivalents of $1.5 million, compared with $2.0 million on December 31, 2022.

Newfound Mechanism Suggests Drug Combination Could Starve Pancreatic Cancer

Retrieved on: 
Monday, October 9, 2023
University of British Columbia, Doctor of Philosophy, Division, New York University Grossman School of Medicine, DON, Kimmelman, Glutaminase, MD, PDAC, Lustgarten Foundation for Pancreatic Cancer Research, Toxicity, Biochemistry, National Cancer Institute, Lung cancer, University, Survival, NYU Langone Health, Nature Cancer, Cancer, Therapy, Glutamine, Environment, Growth, Oxygen, ERK, Mouse, NYU, Pancreatic cancer, Neoplasm, Molecular biology, Enzyme, Radiation therapy, Medical imaging, Pharmaceutical industry

NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

Key Points: 
  • NEW YORK, Oct. 9, 2023 /PRNewswire/ -- A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
  • Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch.
  • DON was designed to starve cancer cells by mimicking glutamine, which unlike glutaminase blockers, broadly inhibits all metabolic pathways that use glutamine.
  • In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer.

Emmaus Life Sciences Reports Management Changes

Retrieved on: 
Wednesday, August 23, 2023
OTCQX, Global Commercial Credit, Sickle cell disease, Gulf Cooperation Council, Senior, Patient, Pharmaceutical industry, Management, Glutamine

TORRANCE, Calif., Aug. 23, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus.  Dr. Niihara was the principal inventor of Endari® (L-glutamine oral powder), which is approved in the U.S. and most of the Gulf Cooperation Council countries for the treatment of sickle cell disease, and long-time the Chairman of the Board and Chief Executive Officer of Emmaus. No rights of the company have been granted to Dr. Niihara in these regards, and he remains a director of the company. 

Key Points: 
  • TORRANCE, Calif., Aug. 23, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported that on August 18, 2023 the Board of Directors, including Yutaka Niihara, M.D., Ph.D, determined that Dr. Niihara would no longer serve as Chief Executive Officer of Emmaus, or as Chairman of the Board, in order to allow Dr. Niihara to pursue business opportunities in Ube, Japan and in India previously initiated by Emmaus.
  • Dr. Niihara was the principal inventor of Endari® (L-glutamine oral powder), which is approved in the U.S. and most of the Gulf Cooperation Council countries for the treatment of sickle cell disease, and long-time the Chairman of the Board and Chief Executive Officer of Emmaus.
  • No rights of the company have been granted to Dr. Niihara in these regards, and he remains a director of the company.
  • We intend to continue to pursue his mission of alleviating suffering among sickle cell disease patients wherever we find them," remarked Mr. Sekulich.

Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman

Retrieved on: 
Thursday, July 13, 2023
Glutamine, Senior, GCC, Marketing, Hemoglobinopathy, HBS, Anti-transglutaminase antibodies, Sale, Patient, Physician, OTCQX, Sickle cell disease, Kingdom, United Arab Emirates, Pharmaceutical industry, Health

TORRANCE, Calif., July 13, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, today announced that it has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari® (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.

Key Points: 
  • "We are delighted to receive marketing authorization for Endari® in Oman, where sickle cell disease is a significant public health issue that affects thousands of patients and their families," said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus.
  • "This approval marks another milestone in our mission to improve the lives of people with sickle cell disease around the world."
  • Emmaus is pursuing additional regulatory approvals for Endari® in other countries where sickle cell disease is prevalent.
  • 1Source: [Sickle cell disease in Oman and HBS Oman: a brief review]( https://medcraveonline.com/HTIJ/HTIJ-04-00100.pdf )

Unlock the Benefits of Trending Supplement, L-Glutamine, With Gundry MD Total Restore

Retrieved on: 
Thursday, June 29, 2023
Food, Lectin, Glutamine, Sugar, N-acetyl-D-glucosamine kinase, Brain, Absorption, Dicarboxylic acid, Weight gain, Protein, Bloating, Health, Dietary supplement, Zinc

LOS ANGELES, June 29, 2023 /PRNewswire/ -- L-Glutamine, a versatile amino acid, has gained significant attention online due to its remarkable health benefits. This trending nutrient is known for its potential to support various aspects of well-being. From helping promote digestive health to aiding in weight management and boosting energy levels, L-Glutamine has become a subject of interest among health-conscious individuals seeking holistic solutions. Those interested in this trending supplement can experience the remarkable effects of L-gGutamine with Gundry MD Total Restore. 

Key Points: 
  • Those interested in this trending supplement can experience the remarkable effects of L-gGutamine with Gundry MD Total Restore.
  • Gundry MD Total Restore is a unique dietary supplement that contains L-Glutamine as one of its key ingredients.
  • With its "gut hero" ingredients and amino acids, Total Restore supports the gut lining, promoting a healthier and lighter-feeling body.†*
    What is Gundry MD Total Restore?
  • With Gundry MD Total Restore users can address the challenges associated with lectin consumption and a compromised gut lining.

Curia Expands Cell Line Development Offering with CHOZN Platform

Retrieved on: 
Tuesday, June 20, 2023
Immortalised cell line, GMP, Sigma-Aldrich, Workflow, CHO, Antibody, Glutamine, Merck, GS, Hamster, Fine chemical, Vaccine

Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.

Key Points: 
  • Following the agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers.
  • The glutamine synthetase GS knockout (GS-/-) cell line of the CHOZN platform is specially designed to help streamline selection, identification and scale-up of high-producing clones ideal for GMP manufacturing of recombinant protein drugs.
  • “The CHOZN GS-/- cell line platform adds a widely accepted and commercially viable cell line to our capabilities.
  • The addition of the CHOZN platform strengthens Curia’s offerings as a complement to its existing proprietary CHO cell line, providing customers with a highly versatile and broadly applicable solution.

Matica Bio Launches MatiMax™ Cell Lines at BIO International Convention

Retrieved on: 
Tuesday, June 6, 2023
Science, Other Science, Biotechnology, Research, Other Manufacturing, Health, Genetics, Manufacturing, Immortalised cell line, GMP, Glucose, CDMO, Ammonia, Glutamine, Nitrogen, Fine chemical

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.

Key Points: 
  • Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the GMP production of cell and gene therapies, today unveiled the company’s new MatiMax™ cell lines at the BIO International Convention, taking place in Boston, MA.
  • Proprietary to Matica Bio, MatiMaxTM HEK293 and HEK293T cell lines have been rigorously optimized to enable:
    Faster doubling times – Reaching as low as 17 hours, which can significantly shorten processing timelines; 30% faster than industry standards
    “The current industry standard for media-based cell line development — typically focused on a limited set of factors, such as glucose, glutamine, nitrogen and ammonia — can potentially limit scalability, which is mission critical when selecting cell lines during the early stages of cell and gene therapy development to stay competitive,” said Michael Stewart, Matica Bio’s chief technology officer.
  • “We already have several clients currently using MatiMaxTM lines, which have immediate availability and attractive licensing terms.
  • Our objective is to empower biopharmaceutical developers to achieve their clinical and commercial goals, and, ultimately, treat more patients.”
    For more details about the new MatiMaxTM cell lines, visit www.maticabio.com .

Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA

Retrieved on: 
Wednesday, May 31, 2023
Senior, NHRA, Sale, Qatar, Patient, OTCQX, Sickle cell disease, Kingdom, United Arab Emirates, Safety, Pharmaceutical industry, Glutamine

TORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.

Key Points: 
  • TORRANCE, Calif., May 31, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a leader in sickle cell disease treatment, announced today that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA) granting marketing authorization for the commercial distribution and sale of Endari® in the Kingdom of Bahrain.
  • Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of Emmaus, commented, "We are grateful that Bahrain officials have seen fit to make Endari available to sickle cell patients in the country.
  • George Sekulich, Senior Vice President of Global Commercialization of Emmaus, added, "The approval from the NHRA is further validation of the safety and efficacy of Endari.
  • We look forward to working with our partner, Gulf Pharmacies, to make Endari available to the sickle cell disease patients in the country.